5808

Biocon reports 4% rise in quarterly revenues

Net profit up 154% to Rs.249 cr, mostly due to an exceptional item; excluding the one-time gain, profit falls 30%
Comment E-mail Print Share
First Published: Fri, Apr 26 2013. 08 08 AM IST
Biocon said that it received $20 million from US drug maker Mylan Inc. as an upfront payment related to its deal on insulin products. Photo: Aniruddha Chowdhury/Mint
Biocon said that it received $20 million from US drug maker Mylan Inc. as an upfront payment related to its deal on insulin products. Photo: Aniruddha Chowdhury/Mint
Updated: Fri, Apr 26 2013. 11 57 PM IST
Bangalore: Statins and insulin maker Biocon Ltd reported a weak 4.3% year-on-year (y-o-y) increase in revenue to Rs.649 crore for the March quarter, as sales of its core biopharmaceutical products fell. Biopharmaceutical revenue fell to Rs.464 crore from Rs.471 crore in the year-ago quarter.
Net profit for the March quarter rose 154% year-on-year to Rs.249 crore, mostly due to an exceptional item. Excluding the one-time gain, profit fell 30%.
Biocon said that it received $20 million from US drug maker Mylan Inc. as an upfront payment related to its deal on insulin products. In February, India’s biggest biotechnology company signed a deal with US drug maker Mylan for an exclusive collaboration for the development and commercialization of generic versions of its three insulin analog products globally.
For the current year, the company said it expected revenues to rise in line with its research and development (R&D) spend.
“We expect our R&D costs to increase in line with the progress being made by our generic biologics and novel molecules. Revenues should keep pace with the increasing R&D investments, as we gain further traction in emerging markets this fiscal,” Biocon said in a statement.
In the year ended March, R&D costs rose 20% to Rs.164 crore, but fell 18% in the fourth quarter.
Biocon also announced it would pay a special dividend of Rs.2.50 a share and appointed Daniel Bradbury, former chief executive at US-based Amylin Pharmaceuticals Llc, to its board of directors.
Comment E-mail Print Share
First Published: Fri, Apr 26 2013. 08 08 AM IST
blog comments powered by Disqus
  • Wed, Apr 23 2014. 05 42 PM
  • Wed, Apr 16 2014. 06 11 PM
Subscribe |  Contact Us  |  mint Code  |  Privacy policy  |  Terms of Use  |  Advertising  |  Mint Apps  |  About HT Media  |  Jobs
Contact Us
Copyright © 2014 HT Media All Rights Reserved